Asset Details
Do you wish to reserve the book?
An Open-Label Safety and Pharmacokinetics Study of Duloxetine in Pediatric Patients with Major Depression
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
An Open-Label Safety and Pharmacokinetics Study of Duloxetine in Pediatric Patients with Major Depression
Do you wish to request the book?
An Open-Label Safety and Pharmacokinetics Study of Duloxetine in Pediatric Patients with Major Depression
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
An Open-Label Safety and Pharmacokinetics Study of Duloxetine in Pediatric Patients with Major Depression
2012
Overview
Objective:
This preliminary, 32-week study assessed the safety, tolerability, and pharmacokinetics of duloxetine in pediatric patients (aged 7–17 years) with major depressive disorder.
Methods:
Patients received flexible duloxetine doses of 20–120 mg once daily, with dose changes made based on clinical improvement and tolerability. Pharmacokinetic samples were collected across all duloxetine doses, and data were analyzed using population modeling. Primary outcome measures included treatment-emergent adverse events (TEAEs), vital signs, and Columbia-Suicide Severity Rating Scale (C-SSRS).
Results:
Of the 72 enrolled patients, 48 (66.7%) completed acute treatment (18 weeks) and 42 (58.3%) completed extended treatment. Most patients (55/72; 76%) required doses ≥60 mg once daily to optimize efficacy based on investigator judgment and Clinical Global Impressions-Severity score. Body weight and age did not significantly affect duloxetine pharmacokinetic parameters. Typical duloxetine clearance in pediatric patients was ∼42%–60% higher than that in adults. Four patients (5.6%) discontinued due to TEAEs. Many (36/72, 50%) patients experienced potentially clinically significant (PCS) elevations in blood pressure, with most cases (21/36, 58%) being transient. As assessed via C-SSRS, one nonfatal suicidal attempt occurred, two patients (2.8%) experienced worsening of suicidal ideation, and among the 19 patients reporting suicidal ideation at baseline, 17 (90%) reported improvement in suicidal ideation.
Conclusion:
Results suggested that pediatric patients generally tolerated duloxetine doses of 30 to 120 mg once daily, although transient PCS elevations in blood pressure were observed in many patients. Pharmacokinetic results suggested that adjustment of total daily dose based on body weight or age is not warranted for pediatric patients and different total daily doses may not be warranted for pediatric patients relative to adults.
Publisher
SAGE Publications,Mary Ann Liebert, Inc
Subject
/ Antidepressive Agents - administration & dosage
/ Antidepressive Agents - adverse effects
/ Antidepressive Agents - pharmacokinetics
/ Blood Pressure - drug effects
/ Child
/ Child & adolescent psychiatry
/ Depressive Disorder, Major - drug therapy
/ Dose-Response Relationship, Drug
/ Female
/ Humans
/ Kinetics
/ Male
/ Psychiatric Status Rating Scales
/ Thiophenes - administration & dosage
/ Thiophenes - adverse effects
